Archives
-
o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics
13 August, 2021
-
o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics
05 August, 2021
-
Digital brain biomarker company Monument Therapeutics raises £2.6 million
20 July, 2021
-
o2h Ventures backed Arecor Granted Key US Patent
14 May, 2021
-
o2h Ventures backed Small Pharma Raises Cash to Fund Reverse Takeover on Toronto Stock Exchange
12 May, 2021
-
o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200m Option License Agreement
11 May, 2021
-
Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year
16 April, 2021
-
University of Sussex and o2h Ventures Announce Creation and Investment in Stingray Bio, a Company for New Oncology Drugs Targeting the LMTK3 Kinase Pathway
08 April, 2021
-
The o2h human health S/EIS flagship fund – Fully Deployed
01 April, 2021